Technical Analysis for AYTU - Aytu BioScience, Inc.

Grade Last Price % Change Price Change
F 5.385 3.16% 0.17
AYTU closed up 3.16 percent on Friday, May 14, 2021, on 43 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 17
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical AYTU trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 3.16%
Lower Bollinger Band Walk Weakness 3.16%
Earnings Movers Other 3.16%
Outside Day Range Expansion 3.16%
Wide Bands Range Expansion 3.16%
Oversold Stochastic Weakness 3.16%
New 52 Week Closing Low Bearish 1.51%
Lower Bollinger Band Walk Weakness 1.51%
Older End-of-Day Signals for AYTU ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits 2 days ago
Up 3% 3 days ago
60 Minute Opening Range Breakout 3 days ago
Up 2% 3 days ago
Up 1% 3 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aytu BioScience, Inc. Description

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Prostate Cancer Urology In Vitro Alcohols Hormones Fertility Ketones Testosterone Imaging Agent Infertility Urinary Tract Infection Urinary Tract Infections Company's Pipeline In Vitro Diagnostic Device Male Infertility Androstanes Hypogonadism

Is AYTU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.0
52 Week Low 5.1
Average Volume 690,213
200-Day Moving Average 9.07
50-Day Moving Average 7.19
20-Day Moving Average 6.19
10-Day Moving Average 5.66
Average True Range 0.39
ADX 22.05
+DI 10.84
-DI 29.22
Chandelier Exit (Long, 3 ATRs ) 6.04
Chandelier Exit (Short, 3 ATRs ) 6.26
Upper Bollinger Band 7.37
Lower Bollinger Band 5.00
Percent B (%b) 0.16
BandWidth 38.39
MACD Line -0.51
MACD Signal Line -0.45
MACD Histogram -0.066
Fundamentals Value
Market Cap 688.9 Million
Num Shares 128 Million
EPS -3.48
Price-to-Earnings (P/E) Ratio -1.55
Price-to-Sales 1.66
Price-to-Book 1.29
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.85
Resistance 3 (R3) 5.82 5.64 5.77
Resistance 2 (R2) 5.64 5.52 5.66 5.75
Resistance 1 (R1) 5.51 5.45 5.58 5.54 5.72
Pivot Point 5.33 5.33 5.36 5.35 5.33
Support 1 (S1) 5.20 5.21 5.27 5.23 5.05
Support 2 (S2) 5.02 5.14 5.04 5.02
Support 3 (S3) 4.89 5.02 5.00
Support 4 (S4) 4.92